Search Results

collaborative neuroscience R&D program with Servier (France) and is the co-founder and CEO of Phrenix Therapeutics , a biotech spin-out from the Neuromedicines Discovery Centre that is developing next-generation therapeutics Prior to these roles this he was Head of Pharmacology at Heptares Therapeutics Ltd., a UK-based biotechnology These successes enabled the US$400M sale of Heptares Therapeutics Ltd. to the Sosei Group Corporation Prior to joining Heptares, Chris was a neuroscience researcher at GlaxoSmithKline, UK (1998-2009).

As a co-founder of Heptares Therapeutics , now called Sosei Heptares , a GPCR-focused drug discovery

Join me to learn more about Chris’s work and his role in founding Heptares which was later acquired by Sosei and became Sosei Heptares . Chris Tate on the web LinkedIn ResearchGate Pubmed Google Scholar Sosei Heptares Wikipedia MRC Laboratory

Alastair Brown (Sosei Heptares), where she is currently a final year Ph.D. student.

Terry Kenakin, “Development of GPCR Ligands as Therapeutic Drugs” is coming up 🧐 Be the first to register ✳️Go to https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs Terry Kenakin, “Development of GPCR Ligands as Therapeutic Drugs” is coming up 🧐 Be the first to register ✳️Go to https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs

“Development of GPCR Ligands as Therapeutic Drugs” with Dr. Terry Kenakin is here! 👉 https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs “Development of GPCR Ligands as Therapeutic Drugs” with Dr. Terry Kenakin is here! 👉 https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs

Terry Kenakin for the 4-week course “Development of GPCR Ligands as Therapeutic Drugs”! 👉 https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs Terry Kenakin for the 4-week course “Development of GPCR Ligands as Therapeutic Drugs”! 👉 https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs

Home → Flash News → ⏳ In case you haven’t heard—registration for “Development of GPCR Ligands as Therapeutic 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Courses ⏳ In case you haven’t heard—registration for “Development of GPCR Ligands as Therapeutic 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr.

Sponsors GPCR Retreat Program < Back to schedule Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Several of these targets are being developed for potential new therapeutic strategies in ovarian and

GPCR University: "Development of GPCR Ligands as Therapeutic Drugs." 🗓 Dates: March 20 - April 10, 2025 deep insights into GPCR drug candidates and learn the critical assays and techniques required to bring therapeutic 🔗 https://buff.ly/lVEcRUc #GPCR #DrugDevelopment #Pharmacokinetics #TherapeuticDrugs #OnlineCourse # GPCR University: "Development of GPCR Ligands as Therapeutic Drugs." 🗓 Dates: March 20 - April 10, 2025 deep insights into GPCR drug candidates and learn the critical assays and techniques required to bring therapeutic

essential additional elements to GPCR discovery programs that extend the discovery process and increase therapeutic essential additional elements to GPCR discovery programs that extend the discovery process and increase therapeutic

subtype-selective precision by combining allosteric modulation with light control, paving the way for new therapeutic subtype-selective precision by combining allosteric modulation with light control, paving the way for new therapeutic

ecosystem to support researchers worldwide and expand access to high-performance tools for GPCR-targeted therapeutics ecosystem to support researchers worldwide and expand access to high-performance tools for GPCR-targeted therapeutics

He is pioneering the investigation of animal toxins acting on GPCRs, the largest therapeutic target class His strongest expertise lies in therapeutic target identification and all the steps from venom manipulations pharmacological properties of these new ligands are deemed exceptional, a lead optimization is realized and its therapeutic

Pina Cardarelli, CSO for GPCR Therapeutics Inc., based in South Korea, has recently been named President of GPCR Therapeutics, USA, a newly incorporated Biotechnology company in the Bay Area. The company’s mission is to discover and develop highly effective cancer therapeutics by targeting heteromers She was an integral contributor to two therapeutics that are FDA approved, Yervoy and Opdivo. patents including anti-PD-1 patents, 22 EP patents, and greater than 100 global patents centered around therapeutic

I then started my career at Evotec before moving to Domain Therapeutics (called Faust pharmaceutical chemistry. 6 years ago I decided to take on a new challenge by taking the position of CSO at Confo Therapeutics Christel Menet on the web Hyphen Projects GPCRS Drug Discovery Confo Therapeutics LinkedIn Dr.

Milligan is the co-founder of both Caldan Therapeutics (2015) which discovers novel therapeutics for indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases and Keltic Pharma Therapeutics

bases for ligand binding and efficacy to help optimize the design and engineering of more efficacious therapeutics perspective in the pursuit of receptor subtype-specific ligands, a major aspect to achieve safer, on-target therapeutics The Sunahara lab has also been developing protein-based therapeutics using structure-guided design and A notable therapeutic is an enzyme that hydrolyzes cocaine. as a treatment for cocaine abuse, a debilitating disease that would require long-term and sustained therapeutic

He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics of GPCRs in disease states to help test the feasibility of using protein-targeted degradation as a therapeutic Maddi is currently a second year Ph.D. student in the Molecular Pharmacology and Therapeutics (MPaT)

Juan José Fung is a Principal Scientist at GPCR Therapeutics, Inc , a drug discovery company focused Juan José Fung on the web LinkedIn GPCR Therapeutics Dr. GPCR Ecosystem Enjoying the Dr.

He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics

He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics

company supporting pharmaceutical, life science, and academic scientists in the development of new therapeutics analysis of drug action and is known for applying binding kinetics to the development of effective therapeutics

I aim to discover new therapeutic approaches, and druggable molecules or refine canonical drug targets while performing various cell-based experiments to understand the binding, activation, and signaling of therapeutically

He is the scientific founder of two biotech companies, ModMab Therapeutics , and AntlerA Therapeutics

In 2016, I joined a company that specialized in therapeutic candidate discovery targeting GPCR ( Confo Therapeutics ) as a team and project leader for antibody discovery for metabolic and inflammatory diseases

Biotech founder Ajay Yekkirala shares how AI, GPCRs, and bold questions are driving next-gen pain therapeutics rerouted his path toward a breakthrough GPCR research career The inside story behind founding Blue Therapeutics Driven by the opioid crisis and the lack of non-addictive pain treatments, Ajay co-founded Blue Therapeutics

Award and the Goodman and Gilman Award from the American Society for Pharmacology and Experimental Therapeutics They explored the evolution of the field, allosteric modulation concepts, and potential therapeutic approaches Arthur will work on designing ligands for specific receptors, aiming to create biased agonists for therapeutic Yamina discussed the potential of autoantibodies and allosteric modulation in the context of disease and therapeutic endogenous allosteric ligands and the possibility of using a neutral allosteric ligand as a preferred therapeutic

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics